Miracle Bio Secures Tens of Millions in Angel Funding Led by Langrun Lifang, with Participation from Hainan Yinsong and Star Capital

Recently, it has been learned that Suzhou Malik Biotechnology Co., Ltd.Completed tens of millions of RMB in angel financing. This round of financing was led byLangrun LifangLead investor, with existing shareholders as co-investorsHainan Yinsongand New ShareholdersStarry Sky Capital. This round of financing will be used to further advance the clinical registration and R&D iteration of two pipelines, as well as to strengthen the company’s professional team. Since its establishment, Malik has completed cumulative financing rounds.Nearly 100 million yuan。

Established in 2021 and led by a team of PhD holders who returned to China from the United States, Malik Biotechnology has gathered a group of high-level R&D professionals engaged in biomedical research both domestically and internationally. Leveraging its core microRNA technology, the company has successfully built an independent innovation technology platform. Through groundbreaking methodological advances, Malik has filled the gap in international early diagnostic technologies for Alzheimer’s disease (AD), addressed key challenges in miRNA-based diagnostics, and achieved full-chain, all-scenario application of AD diagnostic technologies. Meanwhile, Malik Biotechnology’s miRNA technology platform is also dedicated to the field of early cancer screening, providing highly accurate and sensitive biotechnological support for the auxiliary diagnosis of early-stage cancer.

Dr. Su Chang, Founder, Chairman, and CTO of Malikstated: “We are deeply grateful for the trust and support of both new and existing shareholders. Leveraging its core miRNA technology platform, Suzhou Malik Biotechnology Co., Ltd.’s R&D team has pioneered unique core methodologies and demonstrated exceptional execution capabilities.More than a year after project initiation, successfully completed the R&D and product finalization for two pipelines."This round of financing will help us systematically and efficiently advance subsequent product R&D iterations and initiate clinical trials. We will also continue to strengthen our investment in early-stage innovative platforms to ensure the company’s ongoing exploration of cutting-edge technologies in the miRNA field. Moving forward, the company will maintain sustained R&D investment and a strong competitive mindset, striving to drive technological breakthroughs and product iterations, and achieve commercialization as early as possible."

Lead Investor in This RoundLu Liyang, Founding Partner of Langrun Lifangstated: “We remain firmly bullish on the miRNA-based early diagnosis sector entered by Malik. Ultra-early diagnosis of diseases such as Alzheimer’s disease (AD) and cancer holds significant importance, warranting long-term attention and support from both commercial and social perspectives. Malik’s successful completion of the development and finalization of two products in its early stages, coupled with the provision of data demonstrating high specificity and accuracy, validates the R&D capabilities of its miRNA platform. We look forward to the clinical progress of these products.”